INVANZ FOR INJECTION 1 gvial

Country: Singapore

Language: English

Source: HSA (Health Sciences Authority)

Active ingredient:

ERTAPENEM SODIUM

Available from:

MSD PHARMA (SINGAPORE) PTE. LTD.

ATC code:

J01DH03

Dosage:

1g/vial

Pharmaceutical form:

INJECTION, POWDER, FOR SOLUTION

Composition:

ERTAPENEM SODIUM 1g/vial

Administration route:

INTRAVENOUS, INTRAMUSCULAR

Prescription type:

Prescription Only

Manufactured by:

FAREVA Mirabel

Authorization status:

ACTIVE

Authorization date:

2002-03-23

Patient Information leaflet

INVANZ 
SG-MK0826-IV/IM-072014 
(Ertapenem for Injection) 

1 

PRODUCT CIRCULAR   

INVANZ® 
(Ertapenem for Injection) 

I.  THERAPEUTIC CLASS 

INVANZ
* [/sg_wm_2214.html#1]
  [/sg_wm_2214.html#1](Ertapenem
for Injection) is a sterile, synthetic, long-acting, parenteral, 1-β methyl-carbapenem 
that is structurally related to beta-lactam antibiotics, such as penicillins and cephalosporins, with activity 
against a wide range of gram-positive and gram-negative
aerobic and anaerobic bacteria. 

II.  MICROBIOLOGY 

Ertapenem has 
in vitro
  activity against a wide range of gram-positive and
gram-negative aerobic and 
anaerobic bacteria. The bactericidal activity of ertapenem
results from the inhibition of cell wall synthesis 
and is mediated through ertapenem binding to penicillin binding proteins (PBPs). In 
Escherichia coli
, it 
has strong affinity toward PBPs 1a, 1b, 2, 3, 4 and 5 with preference for PBPs 2 and 3. Ertapenem has 
significant stability to hydrolysis by most classes of beta-lactamases, including penicillinases, and 
cephalosporinases and extended spectrum
beta-lactamases, but not metallo-beta-lactamases. 

INVANZ has been shown to be active
against most strains of the following microorganisms 
in vitro
 and in 
clinical infections (see INDICATIONS): 

AEROBIC AND FACULTATIVE GRAM-POSITIVE MICROORGANISMS: 
Staphylococcus aureus
 (including penicillinase-producing strains) 
Streptococcus agalactiae 
Streptococcus pneumoniae (penicillin susceptible isolates only)

Streptococcus pyogenes 
Note: Methicillin-resistant staphylococci and 
Enterococcus spp 
are resistant to Invanz. 

*

Copyright © 2008 Merck Sharp & Dohme
Corp., a subsidiary of Merck & Co., Inc., Whitehouse
Station, 
NJ, USA. 

Summary of Product characteristics

S-SG-MK0826-IV-IM-102021
PRODUCT CIRCULAR
INVANZ®
(Ertapenem for Injection)
I. THERAPEUTIC CLASS
INVANZ (Ertapenem for Injection) is a sterile, synthetic, long-acting,
parenteral, 1-β methyl-carbapenem
that is structurally related to beta-lactam antibiotics, such as
penicillins and cephalosporins, with activity
against a wide range of gram-positive and gram-negative aerobic and
anaerobic bacteria.
II. MICROBIOLOGY
Ertapenem has
in vitro
activity against a wide range of gram-positive and gram-negative
aerobic and
anaerobic bacteria. The bactericidal activity of ertapenem results
from the inhibition of cell wall synthesis
and is mediated through ertapenem binding to penicillin binding
proteins (PBPs). In
Escherichia coli
, it
has strong affinity toward PBPs 1a, 1b, 2, 3, 4 and 5 with preference
for PBPs 2 and 3. Ertapenem has
significant stability to hydrolysis by most classes of
beta-lactamases, including penicillinases, and
cephalosporinases and extended spectrum beta-lactamases, but not
metallo-beta-lactamases.
INVANZ has been shown to be active against most strains of the
following microorganisms
in vitro
and in
clinical infections (see INDICATIONS):
AEROBIC AND FACULTATIVE GRAM-POSITIVE MICROORGANISMS:
Staphylococcus aureus
(including penicillinase-producing strains)
Streptococcus agalactiae
Streptococcus pneumoniae
(penicillin susceptible isolates only)
Streptococcus pyogenes
Note: Methicillin-resistant staphylococci and
Enterococcus spp
are resistant to INVANZ.
AEROBIC AND FACULTATIVE GRAM-NEGATIVE MICROORGANISMS:
Escherichia coli
Haemophilus influenzae
(Beta-lactamase negative isolates only)
Klebsiella pneumoniae
Moraxella catarrhalis
ANAEROBIC MICROORGANISMS:
Bacteroides fragilis
and other species in the
B. fragilis
Group
Clostridium
species (excluding
C. difficile
)
Eubacterium
species
Peptostreptococcus
species
Porphyromonas asaccharolytica
Prevotella
species.
The following
in vitro
data are available, but their clinical significance is unknown.
INVANZ exhibits
in vitro
minimum inhibitory concentration